This page uses content from Wikipedia and is licensed under CC BY-SA.

Fasinumab

Fasinumab
Monoclonal antibody
Type?
SourceHuman
TargetHNGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6406H9896N1700O2026S46
Molar mass144.6 kg/mol g·mol−1

Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]

This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.

It is currently at Phase III trials.

See also

References